Breakthrough Invasive Mold Infections in Hematologic Cases: Relevance of the Host's Factors.

Finally, patients who had received >2 prior lines of treatment (55.6% [5/9] vs 21.4% [6/28], P = .091) and those with a proven or probable diagnosis per the EORTC criteria (88.9% [8/9] vs 57.1% [16/28], P = .087) showed a trend toward a higher attributable mortality at day 30.

also in 53,322 other papers

In our cohort, the incidence of bIMI, taking into account the duration of exposure (ie, number of days of therapy), was numerically higher for micafungin, although the differences did not reach statistical significance.

also in 111,027 other papers